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Objective: To determine the performance of FDA vital staining method in detecting viability
of acid fast bacilli in comparison with culture and also its correlation with conventional
drug susceptibility testing results for isoniazid and rifampicin. Design: The study was
conducted from Jan 2014 to June 2015. Sputum samples of patients taking either Cat I or
Cat II anti-TB treatment were tested by Ziehl Neelsen and FDA staining, culture and
susceptibility to rifampicin and isoniazid at the end of intensive phase. Results: Of the
100 ZN positive specimens, 74 were FDA positive of which 70 were reported positive by both
the readers. All specimens having higher grades (2+ and 3+) by ZN were positive by FDA
staining. 87.88% of 1+ and 45% of scanty smears were positive by FDA staining. MTB was
isolated in 75 specimens of which 72 were positive by FDA. Two culture negative specimens
were FDA positive. FDA staining had sensitivity and specificity of 96% and 92% respectively.
70.66% of the total culture isolates were MDRTB strains. 2.66% strains demonstrated
monoresistance to each of INH and rifampicin. Conclusion: FDA microscopy can be used
as a simple and rapid TB treatment monitoring tool in resource limited settings to identify
those patients requiring immediate culture and DST test.
 2016 Asian-African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).Introduction sis and effective anti-TB treatment (ATT) is necessary toTuberculosis (TB) remains a global health problem in the
21st century, and multidrug-resistant TB (MDR-TB) has
amplified the problem. Globally, 480,000 new cases of
MDR-TB occur annually, and of these, an estimated 9.0%
also exhibit extensively drug-resistant TB [1]. Early diagno-control this epidemic. TB treatment is administered for a
long duration, usually a minimum of 6 months. Follow-up
at regular intervals is required during the course of treat-
ment to monitor response, as well as for early detection
of drug resistance. Presence of viable organisms during
the course of treatment, especially after the intensive, India.
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the patient [2].
Culture is the reference standard for detecting viability of
Mycobacterium tuberculosis (MTB), the causative organism of
TB, but it takes weeks to obtain results. Automated liquid-
culture systems, such as MGIT 960, reduce the turnaround
time to 2–3 weeks. Most commercially available molecular
techniques detect DNA, which is present and amplified from
both viable and dead bacilli and, therefore, cannot report
organism viability. Furthermore, culture and molecular tech-
niques require expensive infrastructure, equipment, reagents,
and lab expertise.
Peripheral health centers (PHCs) in resource-limited set-
tings usually lack these facilities and rely only on microscopy
as a tool for TB diagnosis and prognosis. Once the patient has
started ATT, the first follow-up sputum examination using
either Ziehl-Neelsen (ZN) or fluorescent-staining methods is
performed at the end of the intensive phase, i.e., 2 months
for Cat I patients and 3 months for Cat II patients [3]. In a pre-
vious study, sputum conversion by microscopy after a 2-
month intensive phase was 75.0%, with a range from 61.7%
to 90.9% in patients with initially strong and weak positive
smears, respectively [4]. Both staining techniques stain live
and dead bacilli. A positive follow-up smear-microscopy
result can occur, even if a patient is responding to treatment.
Limited diagnostic facilities at PHCs force the treatment pro-
vider to continue ATT for a further period of 1 month. This
unnecessary prolongation of treatment may result in extra
burden on the Revised National Tuberculosis Control Program
(RNTCP), unnecessary exposure to highly toxic drugs for
patients, and a missed diagnosis of drug-resistant TB.
Fluorescein diacetate (FDA) is a vital stain, with the tech-
nique based on the principle of intracellular FDA hydrolysis.
Only living cells actively convert the nonfluorescent FDA into
the green fluorescent compound fluorescein following enzy-
matic activity, which is considered a sign of viability [5,6].
The presence of fluorescent bacilli in follow-up specimens is,
therefore, due to viable bacilli and may be indicative of a
drug-resistant strain. This studywas undertaken to determine
the performance of FDA vital staining in detecting viability of
acid-fast bacilli (AFB) in comparison with culture as the gold
standard. Additionally, the results of FDA staining were corre-
lated with those of conventional drug-susceptibility testing
(DST) results for isoniazid and rifampicin.
Materials and methods
This study was conducted in a tertiary care hospital in Mum-
bai, India, after obtaining ethics committee permission.
Patients taking either Cat I or Cat II medication under directly
observed treatment submitted two sputum specimens for ZN
staining at the end of the intensive phase [7,8]. Patients sub-
mitting an insufficient quantity of specimen (<2 mL) for per-
formance of all three tests were excluded from analysis.
Microscopy
Patients whose follow-up sputum specimens demonstrated
the presence of AFB in any of the two specimens submittedfor examination and who were willing to provide written
informed consent were included in the study. To verify the
FDA vital staining technique, 20 smear-positive sputum spec-
imens from newly diagnosed treatment-naı¨ve pulmonary TB
patients and smears prepared from 10 fresh MTB isolates,
including one from the standard strain H37Rv on
Lo¨wenstein-Jensen (LJ) medium, were stained using the
FDA-staining method. All 30 smears were FDA positive. All
20 sputum specimens were then treated with 5% phenol over-
night to kill mycobacteria, followed by FDA staining. These 20
smears were FDA negative.
Two smears were prepared from each of the AFB-positive
specimens and stained with FDA staining. FDA staining was
performed as described by Tsukiyama et al. [9]. All reagents
were procured from Sigma–Aldrich (St. Louis, MO, USA). FDA
stock solution was used to prepare fresh FDA-working solu-
tion. The air-dried, nonfixed smears were stained by FDA-
working solution for 30 min, washed with distilled water,
and decolorized with 0.5% acid alcohol for 3 min. After wash-
ing, the smear was counterstained with 0.5% KMnO4. To ren-
der the smear noninfectious before examination, the slide
was covered with 5% phenol for 10 min [10]. Smears were
examined by fluorescent microscopy at 1000 magnification
using an Olympus CX 21 microscope equipped with a Fluo
Led Blue (480 nm) light-emitting diode (LED) cassette (Fraen
Corporation, Srl, Italy). The presence of bright yellow or
greenish rods against the black background indicated positive
results. A smear was defined as FDA positive if at least one
fluorescent bacillus per 100 high-power fields was observed
[11]. Staining and reporting of smears was performed by two
independent, trained observers and two technical experts.
The results were recorded, but blinded from each other. The
technical experts were also blinded to culture results, which
were available after a few weeks.
Culture and DST
Sputum specimens were digested and decontaminated using
the NALC-NaOH method and inoculated on LJ medium for
MTB isolation as per World Health Organization (WHO) guide-
lines [12]. All cultures were read daily for the first week for
contamination and rapidly growing mycobacterial species
and then weekly thereafter, until growth was detected or after
8 weeks, whichever was later. The recovered isolates were
confirmed as MTB using the SD BIOLINE TB Ag MPT 64 rapid
assay [13]. The susceptibility of these isolates to isoniazid
and rifampicin was tested using the 1% proportion method
on LJ medium as described by Canetti et al. [14]. All proce-
dures were performed in certified Class II biological safety
cabinets, and biosafety Level 2 practices were followed.
Results
One hundred consecutive ZN-smear-positive patients whose
specimens gave confirmed results for all three techniques
(i.e., FDA staining, culture, and DST) were included for
analysis.
Of the 100 ZN-positive specimens, 74 were FDA positive,
and 70 of these specimens were reported as FDA positive by
Table 1 – Comparison of FDA staining and culture results with grading of ZN staining.
ZN grading ZN-P CP CN FDA-P FDA-N
Scanty 40 18 22 18 22
1+ 33 30 3 29 4
2+ 15 15 0 15 0
3+ 12 12 0 12 0
Total 100 75 25 74 26
CN = culture negative; CP = culture positive; FDA = fluorescein diacetate; N = negative; P = positive; ZN = Ziehl-Neelsen.
Table 2 – Comparison of FDA staining with culture results in both Cat I and Cat II patients.
FDA Patients on Cat II Patients on Cat I
CP CN Total CP CN Total
Pos 49 1 50 23 1 24
Neg 1 3 4 2 20 22
Total 50 4 54 25 21 46
CN = culture negative; CP = culture positive; FDA = fluorescein diacetate; Neg = negative; Pos = positive.
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grading of ZN-stained smears, all specimens (100%) having
higher grades (2+ and 3+) were positive by FDA staining, with
87.88% (29/33) of 1+ and 45% (18/40) of scanty smears also pos-
itive by FDA staining (Table 1).
MTB was isolated in 75 specimens, of which 72 were posi-
tive by FDA. Additionally, two culture-negative specimens
were FDA positive. Considering culture as the gold standard,
FDA staining had a sensitivity of 96% and a specificity of
92%. Culture positivity in patients taking Cat I or Cat II anti-
TB regimens was 54.35% and 92.60%, respectively (Table 2).
MDR-TB strains were present in 70.66% of the total culture
isolates. Of these, 69.81% and 30.19% were on Cat II or Cat I
regimen, respectively, and 2.66% of strains demonstrated
monoresistance to isoniazid and rifampicin.
Discussion
Long turnaround times for cultures and false-positive rates
associated with DNA-based molecular-amplification assays
for detection of viable bacteria in specimens necessitates
the need for other rapid, yet accurate tests. This study on
FDA staining, which is a simple and rapid technique, demon-
strated that the test exhibited good sensitivity and specificity
when compared with culture, for the detection of viable
mycobacteria.
FDA is a salt of the green fluorophore fluorescein. The prin-
ciple of FDA staining is based on the ability of FDA to pass
through the hydrophobic cell membrane of viable mycobacte-
ria, followed by rapid hydrolysis of FDA by cell esterases
[15,16], which are assumed to be present only in live cells.
Fluorescein accumulates in the cytoplasm due to the intact
cell wall and reports positive FDA results. When viewed under
an LED fluorescent microscope, live bacilli demonstrate
yellowish-green fluorescence, while dead bacilli lack func-
tional acetyl esterase activity and do not fluoresce.
Here, FDA vital staining demonstrated 96% sensitivity,
92% specificity, 94.74% positive-predictive value, and79.31% negative-predictive value. Other studies have
reported comparable sensitivity and specificity [6,11,17,18].
ZN staining and FDA staining demonstrated 25% and 2%
false-positive rates, respectively, for viable bacteria as com-
pared with results obtained from culture. Microscopy is
now available in all TB centers, and LED microscopy is
being phased in under RNTCP in India. It is recommended
that in follow-up patients, AFB-positive smears should be
stained by FDA immediately to identify microscopy defined
treatment failure and, where possible, be confirmed by
culture.
When FDAwas compared with culture results, five discor-
dant results were observed, with all having grading of either
scanty or 1+ according to the ZN technique. Two were FDA
positive, but culture negative, and three were FDA negative,
but culture positive. The two FDA positive/culture negative
results could either be false positives or true positives.
False-positive FDA results may be due to spontaneous hydrol-
ysis of FDA during storage. This was addressed by preparing
working solution weekly using acetone and avoiding contact
with water, as well as by storing them in aliquots at 20 C.
In these two cases, culture negativity might be the result of
over decontamination of specimens. Furthermore, the viabil-
ity of bacilli as defined by FDA positivity (fluorochrome activa-
tion by enzymatic activity) may not always correspond to
bacillus viability as defined by culture (ability to multiply).
This is reportedly observed more commonly in early treat-
ment phases [19]. Three specimens that were positive by cul-
ture were false negative according to FDA staining. This may
be due to poor esterase activity seen in some bacilli. Due to
the long turnaround time of culture results, repeat FDA stain-
ing in discordant cases was not performed.
This study involved follow-up patients on anti-TB treat-
ment. The correlation between the results of ZN staining
and FDA staining and the good performance of FDA staining
in comparison with those obtained by culture gave rise to
two suggestions. Follow-up patients with ZN-smear grades
of 2+ or 3+ should be immediately referred for culture and
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the additional FDA staining. This is because all specimens
with a ZN-smear grade of 2+ or 3+ were FDA positive. The
presence of viable bacilli at follow-up examination is probably
a strong indicator of drug-resistant TB. The results of DST
indicated a high proportion of MDR-TB (70.66%) strains. All
the specimens carrying drug-resistant strains demonstrated
viable bacilli by FDA staining. The association between high
smear grades and DR-TB has also been reported by others
[20,21]. For high-burden settings and where better diagnostic
modalities to rapidly screen for DR-TB, such as Xpert MTB/
RIF assays are not available or where culture facilities are lim-
ited, it is suggested that follow-up ZN smears demonstrating
scanty or 1+ grades should be screened by FDA, and those that
are FDA positive referred for culture.
Twenty-four percent of patients were FDA, as well as cul-
ture positive, but were sensitive to both drugs. This may be
due to delayed smear conversion, which is observed more
commonly in patients taking Cat I treatment [22]. Of the 74
FDA-positive specimens, concordance in results of both the
readers were observed in 70, with all four discordant results
exhibiting scanty FDA grading.
An additional finding of this study was the high culture
positivity (92.6%) in patients taking Cat II treatment. Of these,
74% had MDR-TB and 4% demonstrated monoresistance to
rifampicin. As per RNTCP guidelines, Cat II regimens are ini-
tiated when patients have either taken >1 month of Cat I
treatment in the past or failed to respond to Cat I after
5 months of treatment [23]. It is possible that these patients
were harboring a drug-resistant strain to begin with, which
could not be detected due to the nonavailability of recom-
mended DST methods, such as MGIT 960, line-probe assays,
or Xpert MTB/RIF assays, at peripheral centers. The addition
of streptomycin to an already failed regimen would probably
not eliminate these strains; therefore, there is an urgent need
for baseline DST at diagnosis in MDR-TB suspects.
FDA staining may also play a role in infection control. As
per WHO guidelines, two consecutive negative smears and
cultures taken 30 days apart are considered as criteria to
decide noninfectiousness [2]; however, culture has a turn-
around time running into weeks or months. Recently, the
Centers for Disease Control recommended the use of two con-
secutive negative test results by Xpert MTB/RIF assay to con-
sider a patient noninfectious [23]; however, the overall cost
for implementing this in India may be prohibitive. In
resource-constrained settings and given that FDA staining
exhibited good sensitivity and specificity as compared with
culture results, this method can be used for determining dis-
continuation of infection-control measures.
The FDA vital staining technique has some limitations.
The stock solution of the staining reagent needs to be frozen
at 20 C, and the working solution needs to be prepared
daily. Fluorescence fades rapidly; therefore, smears should
be examined as early as possible. Additionally, this technique
does not identify the underlying cause of resistance. In this
study, only positive ZN-stained smears were included.
The cost of the reagents required for FDA staining is simi-
lar to that of AFB or fluorescent staining. A fluorescent micro-
scope is likely available at many centers, as LED technology is
recommended by the WHO [24]. The procedures for prepara-tion of the stock, as well as those for the working solution
for FDA staining, and interpretation of the smear results
require minimal training. Therefore, FDA staining can be used
in peripheral laboratories having only microscopy facilities.
In conclusion, FDA microscopy can be used as a simple
and rapid TB-treatment-monitoring tool in resource-limited
settings to identify those patients requiring immediate cul-
ture and DST. However, studies involving larger numbers of
samples will be needed to establish the value of FDA micro-
scopy in the diagnosis of MDR-TB under RNTCP.
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